BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON , May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( Nasdaq: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will provide an update on the Company’s two
View HTML
Toggle Summary BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress in NurOwn ® ALS Phase 3 Trial  and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
NEW YORK , April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded its proprietary cellular technology platform to include NurOwn®-derived
View HTML
Toggle Summary Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK , March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly
View HTML
Toggle Summary BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a European-wide patent titled 'Mesenchymal Stem
View HTML
Toggle Summary BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
Enrollment Announced During MS Awareness Week NEW YORK and CLEVELAND , March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the
View HTML
Toggle Summary BrainStorm to Host Business Update Conference Call
Tuesday, March 12th at 8.30am EDT NEW YORK , March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12
View HTML
Toggle Summary BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND , Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular
View HTML
Toggle Summary BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
ZURICH, Switzerland and NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will present at the
View HTML
Toggle Summary BrainStorm Issues a Statement to Patients and Shareholders
NEW YORK , Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement: We will begin by
View HTML
Toggle Summary BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK , Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO, will provide a corporate presentation at the
View HTML
Toggle Summary BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK , Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO, will provide a corporate presentation at the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK , Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will provide a corporate overview presentation
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK , Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will provide a corporate overview presentation
View HTML
Toggle Summary BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK , Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods
View HTML
Toggle Summary BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK , Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods
View HTML
Toggle Summary BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif. , Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies
View HTML
Toggle Summary BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif. , Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds